Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Asha Nayak-Kapoor,Zhonglin Hao,Ramses F. Sadek,Robin Dobbins,Lisa Marshall,Nicholas N. Vahanian,W. Jay Ramsey,Eugene P. Kennedy,Mario Mautino,Charles J. Link,Ray Lin,Stephanie Royer-Joo,Xiaorong Liang,Laurent Salphati,Kari Morrissey,Sami Mahrus,Bruce McCall,Andrea Pirzkall,David H. Munn,John E. Janik,Samir N. Khleif

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

2018

Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) is active as a combination therapy in multiple tumor models.

Keywords:

Tryptophan
Small molecule
Cancer
Cancer research
Immune tolerance
Combination therapy
Kynurenine
Indoleamine 2,3-dioxygenase
Biology
Gastroenterology
Toxicity
Adverse effect
Internal medicine
Medicine
Pharmacokinetics
Pharmacodynamics
Progressive disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations